HC Wainwright Issues Positive Forecast for Oculis (NASDAQ:OCS) Stock Price

Oculis (NASDAQ:OCS) had its price objective upped by HC Wainwright from $44.00 to $47.00 in a research report sent to investors on Tuesday, MarketBeat reports. HC Wainwright currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research note on Tuesday, April 21st. Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Stifel Nicolaus increased their target price on shares of Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Finally, Needham & Company LLC increased their target price on shares of Oculis from $36.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Oculis has an average rating of “Moderate Buy” and an average price target of $45.14.

Oculis Stock Down 6.9%

NASDAQ OCS opened at $30.41 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.96 and a current ratio of 5.96. The firm has a 50-day simple moving average of $27.20 and a 200 day simple moving average of $24.40. Oculis has a twelve month low of $16.00 and a twelve month high of $34.47. The stock has a market cap of $1.76 billion, a PE ratio of -14.28 and a beta of 0.38.

Oculis (NASDAQ:OCS) last released its earnings results on Monday, May 11th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.14). Oculis had a negative net margin of 8,460.67% and a negative return on equity of 61.23%. The company had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.25 million. On average, research analysts forecast that Oculis will post -2.17 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its stake in Oculis by 100.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after purchasing an additional 1,000 shares during the period. Aventura Private Wealth LLC bought a new position in Oculis during the fourth quarter worth about $80,000. Koshinski Asset Management Inc. bought a new position in Oculis during the first quarter worth about $238,000. Millennium Management LLC bought a new position in Oculis during the fourth quarter worth about $312,000. Finally, Marshall Wace LLP bought a new position in Oculis during the second quarter worth about $393,000. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.